TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02686151
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: used after oocyte retrieval
Study: NCT05098938
Drug: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (upper gum area), 50mg, 1 tablet.
Study: NCT04726033
Drug: 64Cu-DOTA-TLX592
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
Study: NCT05804513
Drug: Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
Normalized name: lixisenatide Pen Injector
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: s/c injection
Study: NCT06429397
Drug: Anlotinib and Penpulimab
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
Study: NCT05565573
Drug: Medroxyprogesterone Acetate 500 MG Oral Tablet
Normalized name: medroxyprogesterone acetate 500 MG Oral Tablet
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
Study: NCT06301828
Drug: Envafolimab Injection
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar+SBRT+Envafolimab Injection
Study: NCT06301828
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar+SBRT+Envafolimab Injection
Study: NCT05086224
Drug: Hematoma Local Anesthetic Block Procedure with 1% Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
Study: NCT05086224
Drug: Bier Anesthetic Block Procedure with 1% Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
Study: NCT04488159
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion
Study: NCT05346146
Drug: Sintilimab; Gemcitabine; Albumin-paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
Study: NCT06454448
Drug: Adebrelimab;decitabine;
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
Study: NCT05651789
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
Study: NCT05113186
Drug: Lenvatinib Pill
Normalized name: lenvatinib Pill
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)
Study: NCT05651789
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
Study: NCT05133830
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: OCA will be administered
Study: NCT05133830
Drug: Linerixibat
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat will be administered
Study: NCT05515588
Drug: BI 690517 (C-14)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 (C-14)
Study: NCT05515588
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517
Study: NCT05056220
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
Study: NCT05056220
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
Study: NCT06339242
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
Study: NCT06505941
Drug: umbilical cord mesenchymal stem cell
Normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: umbilical cord mesenchymal stem cell
Study: NCT06475209
Drug: Adebrelimab combined with Apatinib
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
Study: NCT06012500
Drug: Xenon-129
Normalized name: xenon-129
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled contrast for MRI
Study: NCT05688215
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05688215
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05688215
Drug: Quemliclustat
Normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT05688215
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05465798
Drug: MC 3x3
Normalized name: MC-3
DrugBank: TMC-310911 (DB15623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
Study: NCT06439433
Drug: Aminolaevulinic acid (500-mg bottle)
DrugBank: Laevulinic Acid (DB02239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a week for 6 weeks
Study: NCT06439433
Drug: Aminolaevulinic acid (750-mg bottle)
DrugBank: Laevulinic Acid (DB02239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a week for 6 weeks
Study: NCT03294174
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine administered to provide nerve block
Study: NCT06214130
Drug: Sodium valproate 500 MG
Normalized name: Sodium valproate 500 mg gastro-resistant oral tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral intake
Study: NCT06214130
Drug: Valproic Acid 500 MG
Normalized name: valproic acid 500 MG
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral intake
Study: NCT05791409
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Study: NCT05791409
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Study: NCT05247970
Drug: S-309309
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule administered orally
Study: NCT05247970
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup administered orally
Study: NCT05925283
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
Study: NCT05925283
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT05925283
Drug: midazolam and esketamine
Normalized name: esketamine
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT05377658
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT05377658
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT05377658
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT06174688
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injections
Study: NCT04992065
Drug: Evolocumab 140 mg/mL, Repatha®
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL
Study: NCT04695600
Drug: Botulinum Toxin Type A Injection [Botox]
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
Study: NCT06504186
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.
Study: NCT05960565
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A micro-dose of glucagon is added exactly at the same site as insulin is injected.
Study: NCT05821361
Drug: HAIC+Cadonilimab+Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
Study: NCT06241638
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study: NCT05494307
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
Study: NCT05494307
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks
Study: NCT06210542
Drug: ceftazidime avibactam
Normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL
Study: NCT06233201
Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
Study: NCT06233201
Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Study: NCT05723432
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab will be administered intravenously.
Study: NCT05426031
Drug: Protamine fixed dose
Normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg of protamine intravenously (IV), one time use
Study: NCT05426031
Drug: Protamine ratio dose
Normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg of protamine per 100 units of heparin given intravenously (IV), one time use
Study: NCT04809818
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading and maintenance doses of Aspirin administered by oral
Study: NCT04809818
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Loading and maintenance doses of Clopidogrel administered by oral
Study: NCT04809818
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multiple doses of Apixaban administered by oral
Study: NCT04809818
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Dabigatran administered by oral
Study: NCT06193408
Drug: VR-AD-1005
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule
Study: NCT04720716
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab IV d1, Q3W
Study: NCT04720716
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg po
Study: NCT06488482
Drug: nivolumab or pembrolizumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See above
Study: NCT06055257
Drug: sham mPENTOCLO
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo).
Study: NCT04430933
Drug: NC318
Normalized name: Nivolumab and Relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
Study: NCT04430933
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT04430933
Drug: Nab paclitaxel/Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT04430933
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
Study: NCT06281665
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
Study: NCT02650271
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be received entecavir (10 mg/d) before liver resection.
Study: NCT02650271
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be received tenofovir before liver resection.
Study: NCT04774536
Drug: CRISPR_SCD001
Normalized name: Mentha crispa oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT05719506
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nebulizer session with dexmedetomidine preoperative
Study: NCT05719506
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nebulizer session with ketamine preoperative
Study: NCT04877275
Drug: Selinexor (80mg/d)
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;
Study: NCT04877275
Drug: Selinexor (100mg/d)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;
Study: NCT06020066
Drug: EGFR-TK Inhibitor
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
Study: NCT06490068
Drug: LTC004+Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W.
Study: NCT04877275
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40mg/d QW
Study: NCT04930549
Drug: Dapagliflozin 10Mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
Study: NCT04407650
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre
Study: NCT04407650
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre
Study: NCT04903873
Drug: EU101
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EU101 will be administered via intravenous infusion.